Fault line on Canadian border thought dormant for years could cause major earthquake, new study shows
The Tintina fault stretches about 600 miles from northeastern British Columbia into Alaska. It was previously thought to have last been active around 40 million years ago.
But a study published in Geophysical Research Letters earlier this month found signs of more recent activity.
New topographic data collected from satellites, airplanes and drones showed about an 80-mile-long segment of the fault where 2.6 million-year-old and 132,000-year-old geological formations are laterally shifted across the fault.
'We further show that the fault has not ruptured in a major earthquake for at least 12 thousand years, and could generate an earthquake of at least magnitude 7.5 in the future,' the study read. 'The Tintina fault therefore represents an important, previously unrecognized, seismic hazard to the region.'
An earthquake with a 7 to 7.9 magnitude is considered major and can create serious damage, according to Michigan Tech. These types of earthquakes are fairly rare, with only 10 to 15 estimated to occur each year.
Michigan Tech warns earthquakes with a magnitude of 8 or greater, which typically occur only once every year or two, can destroy communities near the epicenter.
'Based on the data, we think that the fault may be at a relatively late stage of a seismic cycle, having accrued a slip deficit, or build-up of strain, of six meters in the last 12,000 years,' Theron Finley, a recent University of Victoria phD graduate and lead author of the new study, explained in SciTechDaily. 'If this were to be released, it would cause a significant earthquake.'
Dr. Michael West, state seismologist at the Alaska Earthquake Center, told the Mail, 'It is one of the least studied fault systems in North America, and that needs to change.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
3 hours ago
- The Independent
‘Game-changing' new Alzheimer's drug could slow progression of disease
An Alzheimer's drug that clears away plaque build-up in the brain could slow progression of the disease and delay the onset of symptoms, early trials have shown. There is currently no cure for the disease, which can severely affect memory and impact people's ability to carry out daily tasks, and the medicines available can only reduce symptoms. But a new drug called Trontinemab is showing promising results, the Alzheimer's Association International Conference in Toronto was told. The drug has been tested on a small number of patients, but 49 out of 54 with early-stage Alzheimer's showed signs of improvement within 28 weeks during a trial, according to Roche, the pharmaceutical company behind the drug. Researchers said 91 per cent of the participants showed a reduction in clusters of protein on their brains, known as amyloid plaques – a key marker of Alzheimer's. Alzheimer's is thought to be caused by an abnormal build-up of this protein around brain cells, while another protein called tau forms tangles within brain cells. These can interrupt the chemical messengers responsible for sending signals between brain cells, according to the NHS. The new drug was found to reduce amyloid proteins to a level so low that scan results on patients taking it for seven months were considered to be 'amyloid negative'. It is thought that the clearance of plaques slows down the progression of the disease and delays the onset of symptoms. 'Alzheimer's disease represents one of the greatest challenges in healthcare today, and tackling it requires early detection and effective therapeutics,' Dr Levi Garraway, chief medical officer of Roche, said. He added: 'Trontinemab is designed to target a key driver of Alzheimer's disease biology more effectively in the brain. Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention.' Professor Sir John Hardy, the chairman of molecular biology of neurological disease at University College London's Institute of Neurology, who was not involved in the trial, told The Telegraph the drug was a 'massive improvement' and works faster than other Alzheimer's drugs on the market. 'There is no doubt this could be game-changing. We hope that if we can use these drugs to people early, we can halt the progression of disease, even before people have symptoms. Now we need to see the size of the clinical effect,' he said. However, the drug does have some side effects, with five participants of 149 (3 per cent) suffering from lesions or swelling in their brains after taking it. But all the participants recovered, and it was considered to be safer than other Alzheimer's drugs that have resulted in 17 per cent of participants experiencing similar side effects. The final part of the trial, which will test the drug on a large number of patients, is yet to be carried out. But if it is successful, health bodies in the UK will need to decide whether it is cost-effective enough to use on the NHS. An estimated 982,000 people are living with some form of dementia, including Alzheimer's, in the UK, with the disease most common in people over the age of 65. But more than a third of people with the condition do not have a diagnosis. The number of those with the disease is expected to rise to 1.4 million by 2040, according to the Alzheimer's Society.
The Sun
5 hours ago
- The Sun
‘Game-changing' Alzheimer's drug could STOP disease in its tracks – as the ‘most powerful weapon' against condition yet
A NEW "game-changing" drug could stop the progression of Alzheimer's disease, early trials suggest. Scientists say the treatment - called trontinemab - could be the most powerful weapon yet against dementia, as they look into giving the drug to people with no symptoms in the hopes of preventing disease. 1 Phase two trial results for trontinemab were presented at he Alzheimer's Association International Conference in Toronto. Researchers said the drug seemed to clear plaques - the abnormal build-up of proteins around brain cells that cause damage and disrupt function - quicker than other drugs licensed to treat Alzheimer's. Trontinemab cleared out plaques and eliminated visible signs of the the disease within 28 weeks for nine out of 10 patients. Drug-maker Roche is now conducting another trial to see if plaque clearance also improves patients' memory. The 18-month study includes 1,600 people, the Telegraph reported. Separate research will examine whether the drug could be given to people without any signs of dementia, just as statins are used to ward off heart disease. Experts hope the drug could stop patients from developing dementia symptoms at all, if it is given early enough. They described the findings so far as 'very promising', suggesting that the drug was much more powerful than existing ones while leading to fewer side effects - as it was able to clear plaques better within seven months that other drugs can in 18 months. Roche's chief medical officer Levi Garraway said: 'Alzheimer's disease represents one of the greatest challenges in healthcare today and tackling it requires early detection and effective therapeutics. 'Trontinemab is designed to target a key driver of Alzheimer's disease biology more effectively in the brain. "Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention. "With plans for phase three trials in both early symptomatic and pre-clinical Alzheimer's disease, we are advancing science with the goal of delaying - and ultimately preventing - progression of this devastating condition.' Prof Sir John Hardy, the chairman of molecular biology of neurological disease at University College London's Institute of Neurology told the Telegraph trontinemab could be 'game-changing'. The scientist, who was the first to identify the role of amyloid plaques in Alzeheimer's, said: 'This is absolutely great news. "It sucks the plaque out of the brain really quickly, much faster than we have seen with lecanemab or donanemab.' Both are Alzheimer's drugs approved for used in the UK, which target amyloid proteins in the brain to slow disease progression. However, neither treatment is offered on the NHS, as the National Institute for Health and Care Excellence (Nice) deemed them too expensive - in large part because patients need frequent scans to monitor for brain swelling and bleeds. Prof Hardy added: 'There is no doubt [trontinemab] could be game-changing. "We hope that if we can use these drugs to people early, we can halt the progression of disease, even before people have symptoms. "Now we need to see the size of the clinical effect. 'These results show it is much faster and safer than previous drugs, which means less monitoring. "That brings down the cost significantly, it means fewer MRI scans, so that would surely mean it would get Nice approval.' Early signs of dementia It's not unusual for your memory to lapse a bit as you get older. But dementia is different from 'just getting old' as it will cause noticeable - rather than gradual - changes to mental abilities and make managing everyday tasks and activities increasingly difficult. The symptoms of dementia may be small to start with, but get worse over time. Below are some examples of possible signs. Memory loss Memory loss is a key sign of dementia. This can include: Forgetting something you were only recently told. You may ask for the same information repeatedly – for example, 'Are the doors locked?' Putting objects in unusual places – for example, putting your house keys in the refrigerator. Being unable to learn new tasks, like how to use a new washing machine. Planning and decision making issues People with dementia can have difficulty with planning and decision making. This can include: Getting very confused when planning or thinking things through. Struggling to stay focused on a single task. Not making informed, careful decisions when dealing with money or looking at risks. Finding it hard to manage regular payments, budgets or monthly bills. Problems with language and understanding In people with dementia, this can manifest as: Having frequent problems finding the right word or regularly referring to objects as 'that thing'. Finding it hard to take part in conversations. Regularly being unable to follow what someone is saying even without distractions. Losing sense of time and place Dementia can cause problems with orientation, including: Losing track of the date, season or the passage of time. Getting lost in a place that is familiar or that should be easy to find your way around – for example, a supermarket. Regularly being unable to follow what someone is saying even without distractions. Problems with vision and perception This can mean having problems making sense of what you see. For example, having difficulty judging distances on stairs, or mistaking reflections or patterns for other objects. Mood and behavioural changes Finally, dementia can also make people act differently or shift their mood. This can mean: Becoming withdrawn and losing interest in work, friends or hobbies. Feeling unusually sad, anxious, frightened or low in confidence. Getting easily upset at home, at work, with friends or in places that usually feel comfortable or familiar. Trials for lecanemab and donanemab showed the drugs helped clear toxic clumps out of the brain and slow nerve damage caused by Alzheimer's by 27 per cent and 35 per cent respectively, over the course of 18 months. But the treatments did present a risk of brain swelling and brain bleeds, meaning patients needed intense monitoring. Trontinemab appears to be safer and cause fewer side effects, with less than five per cent of patients showing abnormal results on their brain scans. All of these cases were quickly resolved, researchers said. The drug - administered by infusion into the bloodstream - also doesn't need to be given a frequently. Upcoming trials will examine the impact of giving the drug to patients once a month for six months, then every three months. Trontinemab has been designed to efficiently bypass the blood-brain barrier, a protective layer of cells that stops harmful substances in the blood stream from attacking the brain and spinal cord. This barrier can make it hard for many drugs to reach the brain. Prof Jonathan Schott, the chief medical officer at Alzheimer's Research UK, told the Telegraph: 'We urgently need a range of treatments for Alzheimer's that are effective and safe for the people affected by this devastating disease. 'Evidence presented at the Alzheimer's Association conference in Toronto on trontinemab is very promising, showing that the drug can effectively and rapidly clear amyloid from the brain, seemingly with very few side effects. 'We now need to see whether these early stage results carry through to later stage clinical trials, which are planned to start later this year, including in the UK. "These trials will show whether the drug is not only safe, but impacts on memory, thinking and quality of life.' He said it was 'exciting' that the drug would now be tested in some people without symptoms under the phase three trials.
BBC News
14 hours ago
- BBC News
People Fixing the World How seaweed is surprisingly useful
From powering cars to feeding farm animals, how using seaweed more can help the planet. We hear how a local business in Barbados is using sargassum seaweed to power cars, providing an eco-friendly alternative for islanders and potentially helping to clear the beaches of smelly seaweed. Also we visit the European company aiming to replace single-use plastics with seaweed-based packaging. And how feeding seaweed to cattle can dramatically cut emissions of planet-warming methane gas. People Fixing The World from the BBC is about brilliant solutions to the world's problems. We release a new edition every week. We'd love you to let us know what you think and to hear about your own solutions. You can contact us on WhatsApp by messaging +44 8000 321721 or email peoplefixingtheworld@ And please leave us a review on your chosen podcast provider. (Image: A person holding clumps of dulse seaweed in Canada, James MacDonald/Bloomberg)
